Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Blink tears

PreclinicalSmall molecule

MMedical University of South Carolina

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dry Eye SymptomsCompleted

Dry Eye SymptomsPreclinical

Completed

Timeline

Expected Milestones

Q2 2027

ApprovedRecruiting

Dry Eye Disease (DED)

NCT07745062

Clinical

Trials by Indication[1]

Dry Eye Symptoms1 trial

Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms

Completed·MMedical University of South Carolina·N/A·NCT00565669·20 enrolled

Dry Eye Disease (DED)1 trial

The Effectiveness of Systane PRO Preservative Free Verses Blink Triple Care Preservative Free in Providing Relief From Multiple Symptoms of Dry Eye Disease, and Its Impact on Daily Functioning and Overall Comfort in Dry Eye Subjects

Recruiting·GGordon Schanzlin New Vision·Approved·NCT07745062·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Blink tears. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Blink tears compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Blink tears. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of South Carolina company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMedical University of South Carolina

Related News